Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study

BACKGROUND: Fingolimod is the first oral agent approved for treatment of relapsing-remitting multiple sclerosis (RRMS). We aimed to evaluate fingolimod effectiveness in a real-world sample of RRMS patients. METHODS: A retrospective, multicentre study in patients treated with fingolimod, whom clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Comi, Giancarlo, Pozzilli, Carlo, Morra, Vincenzo Brescia, Bertolotto, Antonio, Sangalli, Francesca, Prosperini, Luca, Carotenuto, Antonio, Iaffaldano, Pietro, Capobianco, Marco, Colombo, Delia, Nica, Mihaela, Rizzoli, Sara, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479005/
https://www.ncbi.nlm.nih.gov/pubmed/32318950
http://dx.doi.org/10.1007/s10072-020-04380-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479005/
https://www.ncbi.nlm.nih.gov/pubmed/32318950
http://dx.doi.org/10.1007/s10072-020-04380-y

Ejemplares similares